Cas 632364-65-9,Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 7-cyclohexyl-6-(4-fluorophenyl)-N-[(phenylmethyl)sulfonyl]-

632364-65-9

Post Buying Request

Basic information

Product Name: Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 7-cyclohexyl-6-(4-fluorophenyl)-N-[(phenylmethyl)sulfonyl]-
Synonyms:
CAS NO:632364-65-9
Molecular Formula: C26H25FN4O3S
Molecular Weight: 492.574
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 7-cyclohexyl-6-(4-fluorophenyl)-N-[(phenylmethyl)sulfonyl]-(CAS DataBase Reference)
NIST Chemistry Reference: Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 7-cyclohexyl-6-(4-fluorophenyl)-N-[(phenylmethyl)sulfonyl]-(632364-65-9)
EPA Substance Registry System: Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 7-cyclohexyl-6-(4-fluorophenyl)-N-[(phenylmethyl)sulfonyl]-(632364-65-9)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 632364-65-9(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

632364-65-9 Suppliers

Recommended suppliers

632364-65-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 632364-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,2,3,6 and 4 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 632364-65:
(8*6)+(7*3)+(6*2)+(5*3)+(4*6)+(3*4)+(2*6)+(1*5)=149
149 % 10 = 9
So 632364-65-9 is a valid CAS Registry Number.

632364-65-9Upstream product

632364-65-9Downstream Products

632364-65-9Relevant academic research and scientific papers

PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS

-

Page 56, (2010/11/30)

The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 632364-65-9